NanoViricides Inc. (NNVC)

[derf1]

This PR just out should get things moving up again.

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Addresses Shareholders on GSK Bird Flu Vaccine
Monday July 31, 7:30 am ET
NanoViricides, Inc., expects billion dollar plus annual market for its influenza drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--July 31, 2006--Anil Diwan, PhD, NanoViricides' (Pink Sheets: NNVC - News) President, today commented that, "The GSK vaccine has shown significantly better efficacy than the previous vaccines. The GSK vaccine showed an 80% protection in treated individuals. This is still far less than the 95% or better usual clinical protection level of annual influenza vaccines. Using the 80% protection rate, approximately 50% of the population may be expected to show H5N1 bird flu pathology even if a vaccine campaign with the GSK vaccine covered 100% of the world population. The high rates of emergence of resistant viral mutants with existing and developing neuraminidase inhibitor therapies such as Tamiflu(TM), Relenza(TM), or Peramivir(TM), make these therapies unsuitable for widespread strategic use in pandemic containment. In contrast, pre-clinical studies lead us to believe that most of such patients would be curable with our experimental anti-influenza nanoviricides drugs; AviFluCide(TM)-I and FluCide(TM)-I."

ADVERTISEMENT
click here
The Company's CEO, Eugene Seymour, MD, MPH stated, "It is estimated that over 50 million people in the US and Western Europe become clinically ill with human influenza year after year, despite a strong and effective annual vaccine campaign. Approximately 60,000 deaths occur from common influenza annually within the US and Europe alone. We estimate a multi-billion dollar market for our influenza drugs FluCide(TM) and AviFluCide(TM), drugs which early results can be described as a revolution in medicine."

Other announcements by NanoViricides Inc.:

* Dr. Diwan will be speaking at the Novel Vaccines Conference in August in Boston, MA. The vaccine scientific community has shown a particularly strong interest in the nanoviricides(TM) technology and their ability to rapidly create nanoviricides against emerging threats. There is a deep understanding within the scientific community that vaccines and targeted treatments are the two critically important tools for solving the challenge that a virus presents.
* Additional information will be released to its shareholders over the coming weeks.

About NanoViricides - http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.


Contact:

NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
[e-mail]

Source: NanoViricides, Inc.